Literature DB >> 27863911

Crizotinib for ROS1 patients: One small step in biomarker testing, one giant leap for advanced NSCLC patients.

Oscar Juan1, Sanjay Popat2.   

Abstract

Entities:  

Keywords:  Crizotinib; Non-small cell lung cancer; ROS1 fusions; Targeted therapy

Mesh：

Substances：

Year:  2016        PMID： 27863911     DOI： 10.1016/j.lungcan.2016.11.007

Source DB:  PubMed          Journal:  Lung Cancer        ISSN： 0169-5002            Impact factor:   5.705


× No keyword cloud information.
  6 in total

1.  Crizotinib inhibition of ROS1-positive tumours in advanced non-small-cell lung cancer: a Canadian perspective.

Authors:  D G Bebb; J Agulnik; R Albadine; S Banerji; G Bigras; C Butts; C Couture; J C Cutz; P Desmeules; D N Ionescu; N B Leighl; B Melosky; W Morzycki; F Rashid-Kolvear; Clin Lab; H S Sekhon; A C Smith; T L Stockley; E Torlakovic; Z Xu; M S Tsao
Journal:  Curr Oncol       Date:  2019-08-01       Impact factor: 3.677

2.  Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung Cancer.

Authors:  Justin F Gainor; Diane Tseng; Satoshi Yoda; Ibiayi Dagogo-Jack; Luc Friboulet; Jessica J Lin; Harper G Hubbeling; Leila Dardaei; Anna F Farago; Katherine R Schultz; Lorin A Ferris; Zofia Piotrowska; James Hardwick; Donghui Huang; Mari Mino-Kenudson; A John Iafrate; Aaron N Hata; Beow Y Yeap; Alice T Shaw
Journal:  JCO Precis Oncol       Date:  2017-08-16

3.  Prognostic significance of subclassification of stage IIB lung cancer: a retrospective study of 226 patients.

Authors:  Nanchang Yin; Minwen Ha; Yu Liu; Huizi Gu; Zetian Zhang; Wei Liu
Journal:  Oncotarget       Date:  2017-07-11

4.  Identification of RFC5 as a novel potential prognostic biomarker in lung cancer through bioinformatics analysis.

Authors:  Meng Wang; Tian Xie; Yingjie Wu; Qian Yin; Songping Xie; Qingyu Yao; Jie Xiong; Qiuping Zhang
Journal:  Oncol Lett       Date:  2018-07-26       Impact factor: 2.967

5.  Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants.

Authors:  Haiyan Xu; Quan Zhang; Li Liang; Junling Li; Zhefeng Liu; Weihua Li; Lu Yang; Guangjian Yang; Fei Xu; Jianming Ying; Shucai Zhang; Yan Wang
Journal:  Cancer Med       Date:  2020-03-13       Impact factor: 4.452

6.  Real-World Management and Outcomes of Crizotinib-Treated ROS1-Rearranged NSCLC: A Retrospective Canadian Cohort.

Authors:  Amanda J W Gibson; Adrian Box; Winson Y Cheung; Michelle L Dean; Anifat A Elegbede; Desiree Hao; Aliyah Pabani; Randeep Sangha; Dafydd Gwyn Bebb
Journal:  Curr Oncol       Date:  2022-03-14       Impact factor: 3.677
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.